Bioaffinity Technologies, Inc. · NASDAQ:BIAF
Bioaffinity Technologies — Investor Presentation (February 2026)
20 slides from Bioaffinity Technologies's investor presentation, Feb 10, 2026
Slide 1: bioAffinity Technologies Company Presentation
bioAffinity TECHNOLOGIES Company Presentation NASDAQ: BIAF / BIAFW CyPathLung Noninvasive, Accurate Lung Cancer Detection copyright» 2028 bialfinty Tec Ino, 94-2509 4/25 May not be reproduced or distributed without permission,
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation and statements by management or other persons acting by or on behalf of bioAffinity Technologies made in connection with this presentation constitute “forward-looking statements” within the meaning of the sa
Slide 3: Lung Cancer Is A Global Problem and Large Market
Lung Cancer Is A Global Problem and Large Market Most common cancer and leading cause of cancer-related deaths + 2.48 million new cases of lung cancer worldwide in 2022, with 1.8 million deaths annually! o An estimated 19.3 million Americans should have annual lung cancer screening, according to the
Slide 4: Early Detection of Lung Cancer Saves Lives
Early Detection of Lung Cancer Saves Lives 92% of Stage | patients survive 10 years if treated within 1 month of diagnosis! Accurate, early cancer detection can lead to sa yy J + Curative treatment Ua * Long-term survival x + Improving the positive predictive value of screening In 2025, less than 30
Slide 5: Detecting Lung Cancer with Noninvasive CyPath Lung
Improving Lung Health by Tackling the Most Difficult Problem First: Detecting Lung Cancer with Noninvasive CyPath Lung LEN Growing Platform Technology ra \ + Our commercial noninvasive lung cancer test is the first in a pipeline that includes development of companion diagnostics for asthma and chron
Slide 6: CyPath Lung in Action: Patient Case Studies
CyPath Lung in Action: Patient Case Studies* Patient Case Studies Demonstrate CyPatt Risky Procedures Lung Finds Cancer at Curative Stage 1A; Averts “Gloria” case: CyPath® Lung returned a “likely” malignancy result for a patient with Stage 1A mucinous adenocarcinoma later confirmed by biopsy. PET sc
Slide 7: CyPath Lung in Action: Patient Case Studies
CyPath Lung in Action: Patient Case Studies* Case Studies Demonstrate Cancer Detection In Surveillance Period; Earlier Detection of Malignant Ground Glass Nodule “Joan” case: Surveillance in high-risk survivors is challenging. CyPath® Lung returned a “likely” result during monitoring after initial l
Slide 8: CyPath Lung Compares Favorably to Standards of Care
CyPath Lung Compares Favorably to Standards of Care Proven Clinical Utility To Help Detect ig Cancer Noninvasively Lung Cancer Diagnostic Procedure or Test Sensitivity Specificity CyPath* Lung! 92% 87% (individuals at high risk with nodules <20mm) FDG PET imaging? " " (individuals with suspicious lu
Slide 9: CyPath Lung: Physician-Focused, Patient-Friendly, Reimbursed by Insurance
CyPathLung Physician-Focused, Patient-Friendly, Reimbursed by Insurance @ Clinic @ Home @ Laboratory @ Clinic FF) > = ships ‘overnight Physician orders Patient videos, Al-driven automated Physician receives results CyPath” Lung test to ship instructions, personal data analysis of flow within 3 days
Slide 10: Interpreting the CyPath Lung Report
Interpreting the CyPathLung Report =—f,stsssisaroom ms. Pet: 006 JE cotecton Date 882226 lig: Paco Paty Labi, SSnede nowopannes 08 Age Soe 008885, 71 eotve ate 010872028 Scale reflects probability ‘Aecesson Number 10460003 ea of cancer Rewato- 26 20008 aniers Reference Range: >0.00 & <0.50 Unlikely
Slide 11: Significant Healthcare Savings
CyPath Lung Significant Healthcare Savings 2024 study! authored by pulmonologists practicing at Audie L. Murphy Memorial VA Hospital and Brooke Army Medical Center evaluated CyPath” Lungs potential economic impact if added to the standard of care in 2022 s& Conclusion: Significant savings to individ
Slide 12: How the CyPath Lung Test Works
How the CyPath Lung Test Works Flow cytometry interrogates the lung microenvironment + Sputum samples are processed into a single-cell suspension and labelled before data acquisition with antibodies, reagents, labeling agents and TCPP, a synthetic porphyrin taken up by cancer and cancer-related cell
Slide 13: CyPath Lung Market Opportunity
10% 2030 Market Share = $470 MM CyPath Lung Market Opportunity The U.S. Market for CyPath® Lung is poised for significant growth Projected increase in indeterminate pulmonary nodules (IPN) requiring follow-up* 5.000.000 a7 MM z 5 4000,000 a ere a 2 i % 000000 £ 254m 24000000 2025 2026 2027 2028 2028
Slide 14: CyPath Lung Market Opportunity: Surveillance
10% 2030 Market Share = $7.76 MM CyPath Lung Market Opportunity CyPath® Lung Use for Surveillance of Lung Cancer Recurrence Projected increase in Lung Cancer Survivors* 900,000 850,000, 871.580 852,46 833,354 B00 000, 14.241 750,000 Number of Patients 737.789 700,000 718678 680.450 50,000 00.000 202
Slide 15: A Solid Foundation for Growth
A Solid Foundation for Growth Revenue Milestones Achieved in 2025 * 100% increase in CyPath® Lung year-over-year revenue and units sold! + Published multiple case studies and physician testimonials on the human impact of CyPath® Lung + Entered major VA medical centers with lung nodule programs + Pha
Slide 16: Longitudinal Clinical Trial Launches in 2026
Longitudinal Clinical Trial Launches in 2026 Longitudinal study supports inclusion of CyPath® Lung @ @ @ as part of the standard of care for pulmonary nodules e iS) ® Clinical study will evaluate CyPath® Lung performance to support risk stratification, clinical decision-making, detection and survivo
Slide 17: Building on a successful diagnostic platform
Building on a successful diagnostic platform Next in our pipeline: companion diagnostics for asthma and COPD Quantifying lung inflammation for CyPathLung r improved therapy Specificity’ Precision diagnostics match patients to effective treatments and monitor their effectiveness * Companion diagnosti
Slide 18: Management - Innovative, Experienced, Dedicated
Management-— Innovative, Experienced, Dedicated Maria Zannes, JD Founder, CEO & President 0+ years C-suite executive in medical and engineering fields building high= performing corporate teams who build shareholder value MBA, CPA CFO 30+ years in corporate finance including CFO ot CytoBioscience and
Slide 19: Board of Directors
Board of Directors Decades of Successful Leadership from Start-Ups to Global Corporations 0 s 8 @ Steve Girgenti, Executive Peter Knight, Director john Oppenheimer, MD, Director Jamie Platt, PhD , Director Chairman Founding Partner of Generation cli iI Professor of Medicine and Director 20+ years of
Slide 20: Contact
Contact: ooh ee Maria Zannes President & CEO e e e e e mz@bioaffinitytech.com bidAffin Ity oe TECHNOLOGIES bioAffinity Technologies, Inc. 3300 Nacogdoches Road Suite 216 San Antonio, TX 78217 NASDAQ: BIAF / BIAFW May not be reproduced or distributed without permission,
bioAffinity Technologies — Investor Presentation (February 2026) on 6ix